3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Trastuzumab
25
Paclitaxel
22
Cyclophosphamide
20
Docetaxel
17
Taxes
14
Lapatinib
13
Doxorubicin
13
Radiotherapy
12
Bevacizumab
11
Capecitabine
10
Tamoxifen
9
Immunohistochemistry
9
sargramostim
8
Granulocyte-Macrophage Colony-Stimulating Factor
8
Filgrastim
8
Carboplatin
8
Vorinostat
6
Magnetic Resonance Spectroscopy
6
Erlotinib Hydrochloride
6
Chemotherapy, Adjuvant
6
Biopsy
6
Peripheral Blood Stem Cell Transplantation
5
Everolimus
5
liposomal doxorubicin
4
ixabepilone
4
Vinorelbine
4
Neoadjuvant Therapy
4
Immunoenzyme Techniques
4
Gene Expression Profiling
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Neoplasms, Male
×
seviteronel
×
Clear all
NCT02580448
2019-02-01
CLARITY-01
Innocrin Pharmaceutical
Phase 1/2
Completed
175 enrolled